Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 2,100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Not listed Phase 2 Interventional

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050
View directory record Official record
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

NCT02918006
View directory record Official record
Conditions
Influenza
Interventions
VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 28, 2026, 12:58 PM EDT
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 12:58 PM EDT
Recruiting Phase 4 Interventional

Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)

NCT03652753
View directory record Official record
Conditions
Pilon Fracture
Interventions
N-acetylcysteine, Saline
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity Extension Study

NCT01313312
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 12:58 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

NCT00216242
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Saline placebo
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2006 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

NCT03844386
View directory record Official record
Conditions
HIV-1 Infection
Interventions
MVA.tHIVconsv3, MVA.tHIVconsv4, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 12:58 PM EDT
Recruiting Phase 2Phase 3 Interventional

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

NCT06788756
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML)
Interventions
Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Drug
Lead sponsor
Moleculin Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 3 Interventional

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

NCT00126412
View directory record Official record
Conditions
Pheochromocytoma, Neuroblastoma
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
Not listed
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 28, 2026, 12:58 PM EDT
Recruiting Not applicable Interventional

Does Ethyl Chloride Spray Work?

NCT06651788
View directory record Official record
Conditions
Injection Fear, Injection Pain Prevention, Injection Complication
Interventions
Ethyl Chloride, Cold Saline Spray
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Prolotherapy for the Treatment of Chronic Lateral Epicondylitis

NCT00674622
View directory record Official record
Conditions
Lateral Epicondylitis, Tennis Elbow
Interventions
Prolotherapy, Placebo
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 28, 2026, 12:58 PM EDT
Completed No phase listed Observational

Tracking Outcomes in Pain Patients Using Fitness Devices

NCT02420457
View directory record Official record
Conditions
Chronic Pain, Back Pain
Interventions
Epidural injection, Epidural steroid injection as determined by routine care provider
Procedure · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 28, 2026, 12:58 PM EDT
Terminated Phase 1 Interventional Results available

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04478994
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

NCT00725322
View directory record Official record
Conditions
Pain
Interventions
Botulinum Toxin A, Placebo - Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 28, 2026, 12:58 PM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 28, 2026, 12:58 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.

NCT04507126
View directory record Official record
Conditions
Healthy
Interventions
Bacillus Calmette-Guerin (BCG)
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 28, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

NCT04112160
View directory record Official record
Conditions
Pain, Urinary Stone, Urinary Calculi
Interventions
Ketorolac, normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 28, 2026, 12:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
View directory record Official record
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 12:58 PM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 28, 2026, 12:58 PM EDT
Terminated Phase 4 Interventional Results available

Using Saline for Myofascial Pain Syndromes (USAMPS)

NCT02120261
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Normal Saline, Lidocaine Hydrochloride, Triamcinolone acetonide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 28, 2026, 12:58 PM EDT